文献速递肾癌与肾肿瘤

转移性非透明细胞肾细胞癌一线治疗的疗效:国际转移性肾细胞癌数据库联盟结果

Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
PubMed 文献 · Eur Urol Oncol · 2026-01-19

基于国际转移性肾细胞癌数据库联盟,纳入1551例转移性非透明细胞肾细胞癌患者,比较一线免疫肿瘤联合血管内皮生长因子(IOVE)、免疫肿瘤双联(IOIO)、卡博替尼(CABO)、舒尼替尼/帕唑帕尼(SUN/PAZ)或mTOR抑制剂单药的疗效。乳头状RCC中最常见(725例,47%),肉瘤样去分化236例(15%)。不同组织学亚型对各方案反应不同,乳头状RCC中IOVE、IOIO和CABO的客观缓解率(ORR)与中位总生存(OS)优于SUN/PAZ和mTOR;肉瘤样去分化队列中IOIO的ORR最高、中位OS最长。

要点

  • 乳头状RCC中IOVE、IOIO和CABO的ORR与中位OS优于SUN/PAZ和mTOR。
  • 肉瘤样去分化患者接受IOIO的ORR最高(39%)、中位OS最长(31.9个月)。
  • 非透明细胞肾细胞癌各组织学亚型一线治疗疗效存在差异,需组织学特异性策略。

核心结论

  • 不同组织学亚型的转移性非透明细胞肾细胞癌患者一线治疗结局存在差异。
  • 鉴于各方案对不同组织学亚型的活性不同,需要更多组织学特异性策略。

研究设计与样本

  • 国际转移性肾细胞癌数据库联盟(IMDC)的回顾性队列研究。
  • 纳入1551例接受一线IOVE、IOIO、CABO、SUN/PAZ或mTOR单药治疗的转移性非透明细胞肾细胞癌患者。
  • 比较基线特征、临床医生评估的客观缓解率(ORR)和总生存(OS)。

主要发现

  • 乳头状RCC最常见(725例,47%),肉瘤样去分化236例(15%)。
  • 乳头状RCC队列中,IOVE的ORR为31%、中位OS为33.2个月;IOIO为26%和31.9个月;CABO为37%和30.7个月;SUN/PAZ为13%和17.2个月;mTOR为3.4%和13.1个月。
  • 肉瘤样去分化队列中,IOIO与最高的ORR(39%)和最长的中位OS(31.9个月)相关。

关键数值与推荐

  • 乳头状RCC:IOVE的ORR 31%、中位OS 33.2个月;IOIO的ORR 26%、中位OS 31.9个月;CABO的ORR 37%、中位OS 30.7个月;SUN/PAZ的ORR 13%、中位OS 17.2个月;mTOR的ORR 3.4%、中位OS 13.1个月。
  • 肉瘤样去分化:IOIO的ORR 39%、中位OS 31.9个月。

临床怎么用

  • 乳头状RCC可优先考虑IOVE、IOIO或CABO,而非SUN/PAZ或mTOR。
  • 肉瘤样去分化患者可优先考虑IOIO方案。
  • 临床决策应结合非透明细胞肾细胞癌的组织学亚型选择一线治疗。

局限性

  • 回顾性研究设计可能存在选择偏倚。
  • 客观缓解率基于临床医生评估。
  • 部分组织学亚型样本量可能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Real-world evidence on the effectiveness of first-line immuno-oncology (IO)-based combinations or cabozantinib (CABO) over traditional targeted therapies in metastatic non-clear cell renal cell carcinoma (nccRCC) is limited. This study aims to compare the outcomes of first-line therapies for metastatic nccRCC according to histologic subtypes, including papillary renal cell carcinoma (RCC), unclassified RCC, and chromophobe RCC with or without sarcomatoid dedifferentiation. METHODS: Using the International Metastatic Renal Cell Carcinoma Database Consortium, patients with metastatic nccRCC who received (1) IO plus vascular endothelial growth factor (IOVE) combination therapy, (2) IOIO doublet therapy, (3) CABO monotherapy, (4) sunitinib or pazopanib (SUN/PAZ) monotherapy, or (5) mammalian target of rapamycin (mTOR) monotherapy were included. Baseline patient characteristics, clinician assessment of objective response rates (ORRs), and overall survival (OS) were compared across first-line therapy regimens. KEY FINDINGS AND LIMITATIONS: The most common nccRCC histology was papillary found in 725 (47%), and sarcomatoid dedifferentiation was found in 236 (15%) of the 1551 patients included. Within the papillary RCC cohort, ORRs and median OS were, respectively, 31% and 33.2 mo for IOVE, 26% and 31.9 mo for IOIO, and 37% and 30.7 mo for CABO, as compared with 13% and 17.2 mo for SUN/PAZ and 3.4% and 13.1 mo for mTOR. Within the sarcomatoid dedifferentiation cohort, receipt of IOIO was associated with the highest ORR and the longest median OS (39% and 31.9 mo, respectively). CONCLUSIONS AND CLINICAL IMPLICATIONS: Distinct patient outcomes were observed across histologic subtypes. More histology-specific strategies are required given the differential activity of first-line therapy regimens against each nccRCC histology.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Takemura K, Graham J, Maj D, et al. Outcomes of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma Receiving Contemporary or Traditional First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. 2026. PMID: 41558869. doi:10.1016/j.euo.2025.12.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。